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High density iipoprotcins (HDL) consist of a mixture of chemically and functionally distinct families of particles defined by their 
characteristic apolipoprotcin (Apo) cotnposition. The two major lipoprotcin families are lipopro~ein A-! (LP-A-I) and lipoprotein 
A-! : A-It (LP-A-I : A-It). This study describes the isolation of a third minor HDL family of particles referred to as lipoprotcin 
A-[I (LP-A-II) because it lacks APOA-! and contains ApoA-l| as its main or sole apolipoprotein constituent. Because ApoA-II is 
an integral protein constituent of three distinct [ipoprotcin families (LP-A-I:A-I!, LP-A-II:B:C: D:E and LP-A-ll), LP-A-I! 
particles wore isolated from whole plasma by sequential immunoaffinity chromatography on immunosorbcrs with amisera to 
APOA-ll, APOB and APOA-I, respectively. In normolipidemic sul~ects, the concentration of LP-A-II particles, based on APOA-ii 
c~ntent, is 4-18 mg/dl accounting for 5-20% of the total ApoA-il not associatcd with ApoB-containing lipopmteins. The lipid 
composition of LP-A-II particles [s characterized by low percentages of trigiycerides and cholesterol ester:, and a high p~rcentagc 
of phospholipids in compari.~on with lipid composition of LP-A-I and LP-A-! : A.lt. The major part of LP-A-II particles contain 
APOA-II a~ the sole apoiipoprotein constituent; however, small subsets of LP.A.II particles may also contain APOD and other 
minor apolipoprotcins. The I;.pid/protein ratio of LP-A-!I is higher than those of LP-A-I and LP-A-I :A-II. In homo~ygous 
ApoA-I and ApoA-I/ApoC-III deficiencies, LP-A-ll particles are the only ApoA-containing high density iipoprotein with levels 
found to be within the same range (7-13 mg/di) as those of normolipidemic subjects, l-lowcvcr, in contrast to norma! LP-A-II, 
their lipid composition is characterized by higher percentages of triglycerides and chole:;tcrol cstcr~ and a |owcr percentage of 
phospholipids and their apolipoprotein composition by the presence of ApoC-peptides and APOE in addition to ApoA-.lI and 
ApoD. These results show that LP-A-II particles arc a minor HDL family and suggest that, in the absence of Al~A-l-containing 
iipoproteins, ~hey become an efficient acceptor/donor of Ap<K~-peptides and ApoE required for a normal metabolism of 
triglyceride-rleh lipoproteins. Their other possible functional roles in lipid transport remain to be established in future 
experiments. 
Introductiun 
Apolipoprotein (Apo) A-II is the second most abun- 
dant protein of high density lipoproteins (HDL) in 
human plasma aecou,fing for approx. 30% of their 
total protein mass [1-3]. its plasma concentration has 
t Deceased 12 January 1992. 
Abbreviatioqs: VLDL, very low del;sily lipoproteins; LDL, low den- 
sity I[poprm¢ins; HDL, high density lipoproteins; LP, lipoprotein; 
Apo, apolipoprotein. 
Correspondence: P. Alaupovic, Oklahoma Medical Research Foun- 
dalior., 825 NE 13th Street, Oklahoma City,°OK 73104, USA. 
been reported to range between 25-80 mg /d i  [4], with 
more than 90% occurring in the density range !.063- 
1.25 g /ml  [3,5]. in man, ApoA-ll  mainly consists of 
two identical polypeptide chains of M r 87(}7 covalently 
linked by a disulfide bond between the cysteine residues 
at position 6 [!,6]; it occurs, however, in smaller 
amounts in its monomeric form and as a heterodimer 
with ApoE [6,7]. Like ApoA-I, ApoA-il  is a secretory 
protein synthesized as a larger precursor (prepropro- 
tein) containing a prepeptide and a signal peptidc with 
18 and five amino acid residues, respectively [8], 
Whereas the cleavage of prepeptide occurs intra- 
cellularly, the conversion of proprotein to mature 
ApoA-II mainly occurs extracellularly in a reaction 
catalyzed by a procathepsin B-like proteinase [6,9]. 
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ApoA-ll  exists in plasma [n several polymorphic forms 
[10,11], 
Due to its high lipid-binding affinity, ApoA-ll  plays 
a significant role in the formation and structural stabil- 
ity of HDL particles [12-16]. It has been suggested 
from in vitro expe~'iments that ApoA-II inhibits the 
activation of lecithin:cholestcrol acyltransferase by 
APOA-I [17-19] and modulates the activity of hegatic 
triglyceride lipase [20-22]. In a recent study, Carson 
has demonstrated that APOA-I! inhibits factor X acti- 
vation by interfering with the association of t~zstte 
factor (coagulation factor l i d  with factor Vl la  [23]. 
A number of studies have demonstrated that HDL 
consist of several distinct iipoprotein particles differing 
with respect to their particles sizes, densities, chemical 
composition and metabolic properties [24-27]. Among 
these lipoprotein particles identified and diff,:rentiated 
on the bas;s of their apotipoprotein composition [24], 
ApoA-ll  mainly occurs in association with ApoA-I as 
lipoprotein A-! :A-l l  (LP-A-I :A-II) [28-34]. The LP- 
A-I :A-I]  family is a polydisperse system of particles 
present throughout the HDL density range with the 
major part occurring in the HDL 3 subfraction [33,35]. 
Another" lipoprotein form of ApoA-ll  has been re- 
cently identified and characterized as lipoprotein A- 
l l : B : C : D : E  ( L P - A - I I : B : C : D : E  (~r LP-A-I I :B 
complex) in VLDL of patients with Tane.ier disease or 
phengtype V hyperlipoproteinemia [36]. There are also 
a few reports indicating the existence of LP-A-ll parti- 
cles containing ApoA-I! as the major protein con- 
stituent but devoid of ApoA-I and ApoB and first 
detected in HDL of patients with Tan~.ier disease [37]. 
Subsequently, these particles have also been identified 
in low density lipoproteins (LDL) of a patient with 
APOA-I deficiency and planar xanthoma [38], in HDL 
of normolipidemic subjects [39] and patients with vis- 
ceral Leishmaniasis [40I. 
The purpose of this study was to provide informa- 
tion on the concentration, composition and lipoprotein 
subspecies of LP-A-I! particles isolated by im- 
mtmoaffinity chromatography from whole plasma of 
normolipidemic subjects and to compare their proper- 
ties with those of LP-A-ll particles isolated from pa- 
tients with severe forms of APOA-I deficiency. 
Materials  and Methods  
Subjects  
Six normolipidemic subjects, two subjects homozy- 
gous and two subjects heterozygous for APOA-I/ 
ApoC-ll l  deficiency, two subjects homozygous and 
three subjects heterozygous for ApoA-I deficiency, and 
planar xanthoma and one subject homo~gous for 
Tangier disease were studied (Table I). The normo- 
lipidemic subjects were healthy, asymptomatie Cau- 
casians (two women and four men with a mean age of 
47 _+ 14 years) without any history of familial hyper- 
iipoproteinemia or diabetes mellitus. They were non- 
obese and non-smokers except for one subject consum- 
ing ten cigarettes per day. The alcohol consumption 
was below 50 g per week. One of the women was 
premcnopausal and the other was postmenopausal; the 
latter was taking Premarln (1.25 mg per day) and was 
characterized by very high levels of ApoA-! and ApoA- 
!I. The clinical features of two female patients with 
ApoA-I /ApoC- l l l  deficiency and their heterozygous 
TABLE 1 
Cont'et~tration.~ o]" liphis, apoliin~pn~tein.~ aml I.P-A.I! particles 
Subjects Total "l"riglyceridcs ApoA-I ApoA-II ApoA-I! associated 
cholcslero] with LP-A-ll particles 
Normals ]q4 + 37 " 86 +_ 49 162 +_ 73 86 4- 13 8.9 _+ 4.9 
(n=6)  
ApoA-|/ApoC-II I ddicicncy 
tlomtlz~g.ot~:s i 29 15 11 ! 2 !1}.5 
(n = 2) { |118-1491 ( 15-16) ( 111-131 (t)_ 12) 
I lt:terozygotes ! 28 2 ! 88 53 8.5 
{n = 2) (92-163} ( 13 -29) (73-1021 (49-57) (6-I I} 
ApoA-I deficiency 
Homozygolc.,, 133 55 11 I I I0.0 
(n = 2) ( 128-1371 (35-74) 18-141 i7-131 
|leterozygotes 193 ± 16 t I I _+ 65 t(184- l0 78 + 2 10.7±5.5 
(n = 3) 
Tangier disease 81 362 2 t 2 I).0 
(n = 1) 
Values are expressed in m g / d l .  
" Mean + S.D. 
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relatives (patients' mother and .son of one of the pa- 
tients) have been 9reviously reported [41]. Both ho- 
mozygous patients had low levels of total cholesterol 
and triglycerides, very low levels of ApoA-ll and im- 
munochemieally undetectable concentrations of ApoA- 
1 and ApoC-ilI. The heterozygous relatives also had 
low levels of total cholesterol and triglycerides. Their 
ApoA-I levels were between those of the patients and 
normals (Tabm !) and their ApoC-Ill concentrations 
(2.2 mg/dl) were approximately one-third to one-fourth 
of those considered normal for their age and sex (7.0 + 
0.2 mg/dl for males aged 11-14 and 11.3 + 0.4 mg/dl 
foi females aged 51-601 [42]. In another kindred, two 
apparently homozygous patients and three of their 
relatives belong to a recently described variant of 
ApoA-i deficiency [43]. Clinically, both patients were 
characterized by planar xanthoma, xanthelasma and 
corneal opacities, but normal appearance of tonsils and 
no tendon xantnoma; one of the patients had a coro- 
nary bypass surgery when she was 58 years of age. Both 
patients hact moderately low levels of total cholesterol 
and normal levels of triglyceride (Table !). The main 
biochemical abnormalities were the .severe deficiency, 
if not the absence, of ApoA-I and low concentrations 
of ApoA-ll, ApoC-I! (I.! and i.4 mg/dl), APOC-III 
(2.2 and 3.3 mg/dl) and ApoD (6.7 rag/all) but normal 
levels of ApoE (11.2 and 11.7 mg/dl). The apparently 
heterozygous relatives had normal concentrations of 
total cholesterol and triglycerides, but their levels of 
ApoA-! were more than one standard deviation below 
the normal mean values for their age and sex [42]; the 
concentrations of ApoC peptides, ApoD and ApoE 
were in the upper normal range for their age and sex 
[42], The clinical and biochemical features of the ho- 
mozygous Tangier patient have been previously de- 
scribed [36]. None of the dyslipoproteinemic subjects 
was taking drugs known to influence lipid concentra- 
tions with the exception of patients with ApoA-I/ 
ApoC-lll deficiency who were treated daily with fl- 
blockers and soya lecithin. 
Venous blood was drawn into EDTA-ccntaining Va- 
cutainer tubes from normolipidemic and dyslipopro- 
teinemic subjects after an overnight fast and the plasma 
samples were collected by low-speed centrifugation. 
Plasma samples collected at the Henry Ford Hospital, 
Detroit, MI (ApoA-I/ApoC-Ill deficiency), University 
Health Center, Ann Arbor, M! (ApoA-I deficiency) 
and Molecular Disease Branch, NIH, Bethesda, MD 
(Tangier disease) were immediately shipped ~.t 4°C and 
received in Oklahoma City, OK, the next morning. 
Upon receipt, preservatives were added to final con- 
centrations of 500 units/ml penicillin-G, 50 ~g/ml 
streptomycin sulfate, 1.3 mg/ml e-amino caproie acid 
and 0.5 mg/ml reduced glutathione [44]. All blood 
donors signed written informed consents. The proto- 
cols were approved by the Institutional Review Boards. 
Preparation o] hmmmosorber.~ 
To prepare immunosorbers, well-characterized "pan" 
monoelonal antibodies to ApoA-I [45], ApoA-ll [36] 
and ApoB [46] Wel-~ coupled to the cross-linked agarose 
activated with N-hydroxysuccinimide (AffiGcl 111, Bio- 
Rad, Richmond, CA) according to the previously de- 
scribed procedures [34,47]. The binding capacities of 
the anti-ApoA-I, anti-ApoA-ll and anti-ApoB im- 
munosorbers were 0.018 mg of ApoA-I, 0.U27 mg of 
APOA-I! and 0.052 mg of APOB per ml of gel, respec- 
tively. The immunosorbers were stable for more than 6 
months at 4°C without loss of binding capacity. 
Isolation of ApoA-H-containing lipoprotein particles 
The fractionation of LP-A-I :A-II, LP-A-II : B com- 
plex and LP-A-II was performed by a recently de- 
scribed sequential, three-step immunoaffinity chro- 
matography with anti-ApoA-ll, anti-ApoB and anti- 
ApoA-i immunosorbers [43]. 
Crossed hnmunoelectrophoresis 
Immunochemical characterization of LF-A-II parti- 
cles was carried out by crossed immunoelectrophoresis 
performed according to a previously described proce- 
dure [40] using 1% agarose (lndubiose HA37, IBF 
Laboratories, Villeneuve-la-Garenne, France) as the 
supporting medium and a mixture (1 : I, v/v) of 0.06 M 
barbital buffer (pH 8.6) and Tris-HCl, EDTA and boric 
acid solutions (10.5; 0.50; 0.65 g/l), pH 9.(I. Starting 
material was either the ApoA-ll-containing lipoprotein 
particles (retained fraction from the anti-ApoA-ll im- 
munosorber) or the isolated LP-A-il family (unre- 
tained fraction from the anti-ApoA-I immunosorber). 
Lipid and apolipoprote#t analyses 
Neutral lipids were quantified by the gas-liquid 
chromatographic procedure of Kuksis et al. [48] and 
the phospholipid phosphorus content was determined 
by the method of Gerlach and Deutieke [49]. Quantita- 
tive determination of apolipoproteins A-l, A-il, B, 
C-II, C-Ill, D and E was performed by electroim. 
munoassays developed in this laboratory and described 
in several previous reports [34,36,38,47]. Monospecific, 
polyclonai antisera to apolipoproteins A-I, A-ll, B, 
C-II, C-Ill, D and E were prepared in rabbits and 
goats and characterized as previously described [50]. 
Results 
Pin,m, concentrations of ApoA.H associated with LP-A- 
I : A-II and LP.A-II particles 
The fractionation of ApoA-ll-containing lipopro. 
teins was monitored by quantitative determination of 
ApoA-ll in all retained and unretained column frac- 
tions, The absolute values of ApoA-I! associated with 
LP-A-I! particles were calculated on the basis of plasma 
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TAI~LE l! 
Lipid composition of LP-A-ll particles 
Subjects Triglycerides Cht,le stcrol Free Phospholipids 
esters cholesterol 
Normals 0.8 -+ I. l  ~ l [.8 ± 3.7 4.6-+ 2.1 82.8_+4.3 
in = 6) 
ApoA-I/ApoC-lll deficient' 
Homozygotes 2.0 27.6 7.9 62.4 
in  = 2) (I .2-2.8) (15.7-39.6) (7.7-8.2) (49.9-7L9) 
Here roz3'gotes N.D. 8.9 5.2 85.9 
(n = 2) (7.5-10.3) (4.2-6.1) (83.6-88.3) 
ApoA-! deficiency 
Homozygotes 12.1 18.5 6.1 63.2 
(n = 2) (5.3-19.0) (15.8-21.3) (5.0-7.2) (60.2-662) 
Heterozygotes I3.0 14.0 5.9 67.0 
(n = 3) (3.9-19.81 ( ! 1.2-16.21 (4.8-7.5) (61.2-75.91 
Tangier disease ~).4 6. I 3.9 89.6 
( n - - I )  
Values are expressed in ~ .  
Mean _+ S.D. 
N.D.. not detected by gas-liquid chromatography. 
ApoA-I! values and percent distribution of ApoA-ll 
among ApoA-II-containing lipoproteins. After removal 
of LP-A-ll:B complex, the most important criterion 
for the separation of LP-A-II from ApoA-l-containing 
lipoproteins was the immunochemically determined ab- 
sence of ApoA-I in LP-A-il. In normolipidemic sub- 
jects, LP-A-ll represented the minor (10.5 _+ 5.5% of 
ApoA-il) and LP-A-I : A-ll the major (89.5 _+ 5.5% of 
APOA-ll) ApoA-ll-containing lipoprotein devoid of 
ApoB; the concentratiGn of LP-A-II particles ranged 
between 4-18 mg/dl and accounted for 5-20% of the 
total ApoA-II not associated with ApoB-containin[ 
lipoproteins (Table I). Although representing the onb 
ApoA-containing lipoprotein family in homozygous pa- 
tients with either APOA-I/APOC-ill or APOA-i defi- 
ciencies, the mean concentrations of LP-A-ll particle: 
(7-13 mg/di) were only slightly higher than those ol 
normolipidemic subjects (Table I). The levels of LP-A- 
II particles (5-16 mg/dl) in patients heterozygous fol 
APOA-! deficiencies were slightly higher than those oJ 
TABLE Ill 
Apolipoprotem composition of LP-A-ll particles 
Subjects Apolipoproteins if:E) 
A-l l  C-I! C-I l l  D E 
Normals 
(n = 3) 77.4-+ 36 a N.D. N.D. 22.6_+3.6 N.D. 
in  = 2) 100.0 N.D. N.D. N.D. N.D. 
(n = 1 ) 88.7 N.D. N.D. 3.8 7.5 
A p o A - I / A p o C - i l l  deficiency 
Homozygotes (~,.3 N.D. 
in = 2) (56.2-72.3) 
Hetcrozygotcs 86.3 N.D. 
{n = 2) (85.7-86.9) 
ApoA-I ~cfi~iency 
Homo~gotes  50.6 0.4 
(n -- 2) i47.0-54.6) (I).2-0.61 
Hetero~'gote~ 95.8 N.D. 





















N.D.. not detected by electroimmunoassay. 
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normal subjects but essentially in the same range as 
those of homozygotes. Although in patients with Tang- 
ier disease the LP-A-Ii:B complex represented the 
major APOA-!I lipoprotein form [36], a small but mea- 
surable concentration of LP-A-II particles was also 
detected confirming the previously reported presence 
of this lipoprotein family in Tangier disease [37]. 
Lipid and apolipopro~ein composition of LP-A-H parti- 
cles 
The percent lipid composition of LP-A-ll particles 
from normolipidemic subjects, heterozygotes for 
APOA-I/ApoC-lll deficiency and a patient with Tang- 
ier disease was characterized by a negligible content of 
triglycerides, a very high content of phospholipids and 
a low ratio of cholesterol esters/free cholesterol (Ta- 
ble II) in comparison with the lipid composition of 
LP-A-I or LP-A-I:A-II particles [34]. In contrast, the 
lipid composition of LP-A-II from patients homozy- 
gous for either ApoA-I/ApoC-III or ApoA-I deft- 
A 
ANTI-APOA-I I  ~ ~ i~; ! 
ANTZ -APoA-, I ~ ~~ ~::~ ~ ~ ~  
: : " ~ :  ~::, ~ : , ~  ~.,~-~ :~ ; ~ , - ~ ~ i ~  : ~ : i  , 
. , - ~  . ~ - ~ . ~ . . :  , . . ,  . , - . . ~  , r r ~ , - ~ ' ~ : ~ : ~  







Fig, 1. Crossed immunoelectrophoresis of ApoA-ll-containin8 lilm- 
proteins isolated from whole plasma by affinity chromatography on 
an anti-ApoA-ll immnnosorber (the retained fraction). Panel A: 
normolipidemic plasma tested w;ih anti-AlmB (a polyclonal anti- 
serum to AlmB) incorporated in the lower gel, anti-ApoA-I (a 
polyclonal antiserum to AlmA-l) in the intermediate gel and anli- 
APOA-ll (a polyclonal antiserum to ApoA-II) in the upper gel. Panel 
B: plasma from a patient homozygous for ApoA-I/ApoC-III deft° 
ciency tested with a mixture of anti-AlmA-I and anti-ApoB incorpo- 
rated in the lower gel and anti-ApoA-I! in the upper gel. Experimen- 
tal conditions are described in Materials and Methods. 
ciency was characterized by increased percent contents 
of triglycerides and cholesterol esters and a decreased 
relative content of phospholipids (Table II) resembling 
the lipid composition of normal LP-A-I,A-ll and, es- 
pecially, LP-A-I particles rather than that of normal 
LP-A-ll particles. 
In some normolipidemic subjects ApoA-II was the 
only apolipoprotein constituent of LP-A-ll particles 
(Table liD. However, in most normolipidemie subjects 
including heterozygotes for ApoA-! deficiencies, 
ApoA-ll was found to be the major and ApoD the 
minor apolipoprotein. In contrast, the LP-A-II parti- 
cles from homozygous patients with ApoA-I deficien- 
cies contained ApoA-II, ApoE, APOD and ApoC- 
peptides in descending order of their percent contents. 
The lipid/apolipoprotein ratios of LP-A-II particles 
from normolipidemic subjexts (2.2)and heterozygotes 
for ApoA-I deficiency syndromes (22) were identical. 
However, the reduced lipid/apolipoprotein ratio (1.3) 
of LP-A-I! particles from homozygous patients for 
ApoA-I deficiencies reflected increased apolipoprotein 
contents of these particles in the absence of ApoA-I- 
containing lipoproteins. 
lmmunochemical evidence for the heterogeneity of 
ApoA-iI-eontaining lipoproteins and LP-A-H particles 
To identify major ApoA-il-containing lipoprotein 
particles, thc retained fraction from anti-ApoA-ll im- 
mur, o.,t~rber wa:, iested by crossed immunoelec- 
trophoresis with polyclonal antisera to apolipoproteins 
A-I, A-II and APOB. The use of anti-ApoB in the 
lower gel, anti-ApoA-I in the intermediate gel and 
anti-ApoA-ll in the upper agarose gel (Fig. 1, panel A) 
revealed the presence, in normolipidemic plasma, of 
three distinct ApoA-ll-containing lipoprotein particles 
including the precipitin line of LP-A-II:B complex in 
the lower gel, LP-A-I:A-ll rocket in the intermediate 
gel and LP-A-I! rocket in the upper gel. On the other 
itand, in a patient homozygous for APOA-i/APOC-lli 
deficiency, the immunoelectrophoretic pattern (Fig. 1, 
panel B) showed the presence of LP-A-II:B complex 
in the lower gel and LP-A-Ii in the upper gel, but the 
absence of LP-A-!: A-II in the intermediate gel. 
The relatively high percentage contents of ApoD 
and ApoE in LP-A-II particles of homozygous patients 
with ApoA-I deficiency syndromes suggested the possi- 
ble heterogeneity of this lipoprotein family, i.e., the 
occurrence of several LP-A-Ii subfamilies differing in 
their apolipoprotein composition. Testing of LP-A-I! 
with anti-ApoA-I and anti-ApoB sera incorporated 
into the lower gel and anti-ApoA-ll serum in the 
upper gel showed that these particles were devoid of 
ApoA-I and ApoB (Fig. 2, panel A). The use of anti- 
APOD and anti-ApoE in the lower agarose gel and 
anti-ApoA-ll in the upper agarose gel revealed that 
LP-A-il family consisted of the so-called simple LP-A- 
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II particles (LP-A-II particles only containing APOA-ll 
as their protein moiety) fi~rming a rocket in the upper 
gel and complex LP-A-II:D and LP-A-II :E particles 
precipitated as two separate lines in the lower gel (Fig. 
2, panel B). The simple LP-A-ll particles migrated 
faster in the first dimension than complex LP-A-II:D 
and LP-A-II :E particles. To provide additional evi- 
dence for the existence of LP-A- l l :D and LP-A-II: E 
particles, the anti-ApoE serum was incorporated into 
the lower gel and anti-ApoD serum in the upper gel 
(Fig. 2, panel C); ApoE-containing particles were pre- 
cipitated in the lower gel and the LP-A-I i :D particles 
devoid of ApoE formed a precipitin line in the inter- 
mediate gel. When the antisera were reversed (Fig. 2, 
panel D) LP-A-II :D formed a precipitin line ~n the 
lower gel and LP-A-II : E formed a rocket in the inter- 
mediate gel. These experiments, however, have not 
excluded the possible, albeit unlikely, existence of LP- 
A-I! : D : E particles. The distribution of ApoC-peptides 
among these LP-A-II subfractions in homozygous pa- 
tients with ApoA-I deficiency remains to be estab- 
lished in future experiments. 
Discussion 
The chemical and metabolic heterogeneity of HDL 
is due to the presence of discrete lipoprotein families 
of particles defined by their characteristic apolipo- 
protein composition. The application of immunoaffin. 
ity chromatography to the fractionation of HDL parti- 
cles has resulted in the recognition and isolation ol 
LP-A-I and LP-A-I:A-I! as two major ApoA-l-con- 
raining lipoprotein families. The chemical anc 
metabolic uniqueness of these two lipoprotein ram[lie: 
has been demonstrated by several independent studie~ 
[26-34]. The present report confirms and extends pre- 
vious observations [37-40] of a third minor Al;oA-con- 
taining lipoprotein family, LP-A-II, characterized b) 
ApoA-ll as its major protein constituent. 
in normolipidemic subjects, the concentration ol 
LP-A-ll accounted for 5-20% of the total plasm~ 
APOA-II content not as~,~ci':ted with ApoB. A compar. 
[son between the chemical characteristics of LP-A-II 
and LP-A-! and LP-A-I:A-l l  particles isolated fron" 
the same normolipidemie subjects [34] attested to the 
chemical uniqueness of this minor lipoprotein family 
!~1 contrast to LP-A-i and LP-A-I:A-II particles, il 
only contained ApoD as an additional apolipoproteir~ 
constiluent except for a rare presence of a small amounl 
of APOE. Its lipid composition was characterized b~ 
the virtual absence of triglycerides, a significantly higher 
percentage of phospholipids (82.8 +_ 4.3 vs 66.7 + 8A 
and 58.2 + 5.2%, P < 0.01-0.001) and a significantl) 
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Fig. 2. Crossed immunoelectrtJphoresis of LP-A-II particles isolated from whole plasma :,f a patient homo~gous for ApoA-I deficiency b~ 
sequential affinity chron.,.atography on immunosorbers Wl:h anti-Al~)A-Ii ~ntl anli-ApoB sera. Pane[ A: LP-A-I! particles tested wilt 
anti-Ap~A-I and anti-ApoB in the lower get and anti-ApoA-II in the upper get. Panel B: LP-A-II particles tested with anli-ApoD (a polyclona 
anti serum to ApoD) and anli-ApoE (a polyclonal antiserum io ApoE) incorporated in the lower gel and anti-ApoA-ll in the upper gel. Panel C 
LP-A-I! particles tested with anli-Al~E incorporated in Ihe lower gel and anti-ApoD in the upper gel. Panel D: LP-A-II particles tested wilt 
anti-Al'x)D incorporated in the lower gel and anti-ApoE in the upper gel. Experimental conditions are described in Materials and Methnds 
lower percentage of cholesterol esters (11.8 + 3,7 vs. 
24.2 + 6.7 and 32.3 + 4.5%, P < 0.01-0.001) than those 
of homologous LP-A-I and LP-A-i : A-II particles. As a 
consequence, the cholesterol ester/free cholesterol ra- 
tio of LP-A-II particles (2.5 + 1.5) was significantly 
lower than those of LP-A-I (3.9 _+ 1.3) and LP-A-I : A-II 
(5.3 ± 1.2). In addition, the lipid/apolipoprotein ratio 
of LP-A-ll (2.26) was approx. 2-fold higher than thc 
corresponding ratios of LP-A-i (1.24) and LP-A-I : A-II 
(0.90). 
In the absence of ApoA-I, the only detectable 
ApoA-containing lipoproteins are LP-A-il particles, 
the concentration of which does not differ significantly 
from those of normolipidemic subjects or subjects het- 
erorygous for A-I deficiency syndromes. However, there 
are marked differences in the chemical composition of 
LP-A-ll. The lipid profile of LP-A-il from homozygous 
patients was characterized by a significantly higher 
percentage of triglycerides and a lower percentage of 
phospholipids in comparison with those of normal LP- 
A-il. The apolipoprotein composition of LP-A-II from 
homozygotes was characterized by a relatively high 
content of ApoE and, in the case of ApoA-! deficiency, 
presence of ApoC peptides accounting for up to 53% 
of the total protein mass; the protein content of ApoD 
was either within the normal range or markedly de- 
creased. In hypercatabolie states such as Tangier dis- 
ease, the HDL particles are quickly removed from the 
plasma [5t,52] which, judged from the low concentra- 
tion of LP-A-II, also seems to apply to this lipoprotein 
family. It should be pointed out, however, that in 
Tangier disease the major part of ApoA-ll occurs in 
the LP-A-II:B complex particles of very low and low 
densities [361. 
The presence of ApoD and other minor apolipo- 
proteins in LP-A-II particles of normolipidemie and 
dyslipoproteinemic subjects suggested the possible sub- 
species heterogeneity of this lipeprotein family. As 
shown previously for LP-A-I and LP-A-I :A-ll particles 
[34], minor apolipoproteins cannot be equally dis- 
tributed on all LP-A-li particles, because they are not 
present in the same molar ratios. In normolipidemic 
subjects, LP-A-I! particles with ApoA-ll as the sole 
apolipoprotein constituent are frequently the only 
lipoprotein form. However, even in subjects whose 
LP-A-II particles contain both ApoA-ll and ApoD, the 
major [~poprt, tcilJ foim is the simple LP-A-ll with 
APOA-II as the sole protein and the minor form i~ 
LP-A-II:D. The crossed immunoelectrophoretic test- 
ing of ApoA-ll-containing lipoproteins in patients ho- 
mozygous for ApoA-! deficiencies provided evidence 
for the occurrence not only of simple LP-A-II particles 
but also for the presence of separate LP-A-II: D and 
LP-A-II : E particles (Fig. 2). The dishibution of ApoC 
peptides, when present, in these LP-A-I! subspecies 
remains to be established, it should also be pointed out 
that the protein moiety of LP-A-II : E subspecies mainly 
consists ol a rnixed disulfide complex, ApoE-ApoA-)l 
monomer, as previously reported for homozygous pa- 
tients with ApoA-l/ApoC-lll deficiency [53]. 
The origin of LP-A-II particles is not known. How- 
ever, it is quite probable that these particles are formed 
primarily, if not exclusively, in the liver as nascent 
lipoproteins rich in phospholipid and free cholesterol. 
Fractionation of HepG2 cell medium by sequential 
affinity chromatography on concanavalin A and im- 
munosorbers with anti-ApoA-ll and anti-ApoA-I re- 
suited in the identification of a small lipoprotein frac- 
tion co~taining ApoA-li, but not ApoA-I, suggestive of 
LP-A-II particles (Dashti, N., personal communication). 
The previously established usefulness of this cell line as 
a model for studying the formation of LP-A-! and 
LP-A-! : A-I! particles [54,55] may prove to be equally 
useful for further studies on the origin and assembly of 
LP-A-ll particles. 
At the present time we can only speculate about the 
possible physiologic role(s) of ApoA-containing lipo- 
proteins including LP-A-II. It has already been sug- 
gested that LP-A-I or LP-A-I:A-IV particles may 
function as the acceptors of peripheral cholesterol 
[25,56,57] and LP-A-I :A-I! particles as the acceptors 
of lipids and apolipoproteins released during the lipol- 
ysis of triglyceride-rieh lipoproteins or, conversely, as 
donors of these apolipoproteins to newly secreted 
triglvceride-rich lipoproteins of hepatic and intestinal 
origin [58,59]. Evidence presented in this study suggests 
that, in the absence of ApoA-I lipoproteins, LP-A-I! 
particles may function as substilute acceptors and 
donors of lipids, ApoC-peptides and ApoE taking part 
in processes responsible for the catabolism of triglyc- 
eride-rich lipoproteins, in fact, the capacity of LP-A-I! 
particles to bind and incorporate neutral lipids and 
minor apolipoproteins appears to be similar, if not 
greater, than those of LP-A-! and LP-A-I :A-ll. How- 
ever, due to their relatively low plasma concentration, 
the LP-A-II particles may not be functionally as efti- 
cient as LP-A-I:A-ll particles, the most abundant 
ApoA-containing lipoprotein family. Some of the other 
possible roles for LP-A-ll may be to function as a 
precursor, in conjunction with LP-B: C: E particles, in 
the formation of triglyceride-rich LP-A-ll : B:C: D: E 
particles [36], as modulators of hepatic triglyceride 
lipase [2(I-22] and lecithin:cholesterol acyltransferase 
[17-19] activities, as inhibitors of factor X activation 
[23] and as antagonists in processes responsible for the 
removal of cholesterol from peripheral cells [56,57]. 
These possible functional roles remain to be examined 
in future experiments. 
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